Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
about
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Anti-cancer activity of dose-f ...... vanced squamous NSLC patients.
@en
Anti-cancer activity of dose-f ...... vanced squamous NSLC patients.
@nl
type
label
Anti-cancer activity of dose-f ...... vanced squamous NSLC patients.
@en
Anti-cancer activity of dose-f ...... vanced squamous NSLC patients.
@nl
prefLabel
Anti-cancer activity of dose-f ...... vanced squamous NSLC patients.
@en
Anti-cancer activity of dose-f ...... vanced squamous NSLC patients.
@nl
P2093
P2860
P50
P356
P1476
Anti-cancer activity of dose-f ...... dvanced squamous NSLC patients
@en
P2093
Francesca Vanni
Luigi Pirtoli
Mayra Rachele Zarone
Pierfrancesco Tassone
Pierosandro Tagliaferri
Pierpaolo Pastina
Stefania Croci
Susan Costantini
Veronica Ricci
P2860
P304
P356
10.21037/JTD.2017.08.68
P50
P577
2017-09-01T00:00:00Z